BVF »

Alkermes shares owned by BVF

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by BVF from 13F filings

Historical chart of BVF investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by BVF consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by BVF

Quarter filed Position value Share count Share price at filing
2026-06-30 $113M 2.2M 52.40
2026-03-31 $71M 2.0M 35.36

More positions owned by BVF

Revolution Medicines (RVMD)
Kymera Therapeutics (KYMR)
Xoma Royalty Corporation Com New (XOMA)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Gh Research Ordinary Shares (GHRS)
Structure Therapeutics Sponsored Ads (GPCR)
Nektar Therapeutics Com New (NKTR)
Mirum Pharmaceuticals (MIRM)
Xencor (XNCR)
Alkermes SHS (ALKS)
Monte Rosa Therapeutics (GLUE)
Cullinan Oncology (CGEM)
Palvella Therapeutics Inc Ne (PVLA)
Zymeworks Del (ZYME)
Kura Oncology (KURA)

View all positions for BVF

Top funds holding Alkermes

BlackRock
Baker Bros. Advisors
Vanguard Portfolio Management
State Street Corporation
Vanguard Capital Management
Renaissance Technologies
T. Rowe Price Associates
Geode Capital Management
Dimensional Fund Advisors
Deep Track Capital
American Century Companies
Holocene Advisors
Commodore Capital
Wellington Management Company
PRIMECAP Management Company

View all funds holding Alkermes